<DOC>
	<DOCNO>NCT00241839</DOCNO>
	<brief_summary>This study test hypothesis administration xanthine oxidase inhibitor ( allopurinol ) prevent thiazide-induced hyperuricemia , result good blood pressure ( BP ) control African Americans .</brief_summary>
	<brief_title>Uric Acid Hypertension African Americans</brief_title>
	<detailed_description>Thiazide diuretic use treatment hypertension associate many metabolic side effect , include hyperuricemia , gout , insulin resistance , hyperlipidemia . Each condition already highly prevalent African Americans . Our hypothesis thiazide-induced hyperuricemia decrease efficacy thiazide control BP , lead endothelial dysfunction , increase incidence insulin resistance impair glucose tolerance . This hypothesis test randomized , double-blind , placebo-controlled clinical trial 8-10 week duration total 100 African American patient hypertension enrol , randomize , treated follow : 1 . Subjects untreated stage I hypertension receive chlorthalidone ( 25 mg/day ) potassium chloride ( 40 mEq/day ) 4 week . Serum potassium level obtain four week chlorthalidone . If level 3.5 mEg/L , bolus 40 mEq potassium 2 3 time daily give 2 3 day , clinically indicate . A maintenance dose 50 mEq initiate . After least 7 day , randomize add-on allopurinol ( 300 mg/day ) placebo . Treatment continue 8-10 week chlorthalidone , potassium chloride , allopurinol/placebo regimen . 2 . Subjects hypertension control ( i.e . BP &lt; 140/90 ) high stage 1 hypertension ( i.e. , &lt; 160/100 ) single antihypertensive agent two antihypertensive agent switch prior antihypertensive agent chlorthalidone 25 mg/day , potassium chloride ( 40mEq/day ) 4 week . Serum potassium level obtain four week chlorthalidone . If level 3.5 mEg/L , bolus 40 mEq potassium 2 3 time daily give 2 3 day , clinically indicate . A maintenance dose 50 mEq initiate . After least 7 day , randomize add-on allopurinol ( 300 mg/day ) placebo . Treatment continue 8-10 week chlorthalidone , potassium chloride , allopurinol/placebo regimen . The allopurinol ( placebo ) dose adjust achieve serum uric acid level 4 5.5 mg/dL 2 week drug . All subject receive low-sodium diet . The primary endpoint reduction systolic BP . Secondary endpoint measure endothelial function , ambulatory blood pressure , body composition , systemic inflammation , metabolic parameter , oxidant stress , renal hemodynamics .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<criteria>African American ( include black individual bear Caribbean , Africa , Canada , etc . ) Are either untreated antihypertensive agent , average sit clinic BP 140/90 159/99 mm Hg OR subject hypertension control ( i.e . BP le 140/90 ) high stage 1 hypertension ( i.e. , less 160/100 ) single antihypertensive agent two antihypertensive agent ( individual fix dose ARBdiuretic ACEIdiuretic combination also consider monotherapy purpose study . Individuals beta blockade calcium channel blockade coronary artery disease and/or arrhythmia eligible study ) Random spot urine protein/creatinine ratio le 0.5 ( approximates 24hour urinary protein excretion 500 mg/day ) Calculated MDRD GFR great equal 60 ml/min/1.73/m^2 No allopurinol probenecid intake least one month prior study entry Willing able cooperate study procedure Willing travel GCRC Shands Hospital overnight inpatient stay two separate occasion History malignant accelerate hypertension Confirmed total white cell count less 2,500/mm^3 , anemia , thrombocytopenia Known history liver disease Known secondary cause hypertension Known presence diabetes fast blood glucose great equal 126 mg/dL History heart failure , acute myocardial infarction , stroke Î²blocker calcium channel blocker cardiovascular indication lower blood pressure Abnormal EKG require medical intervention History clinical renal biopsy evidence renal parenchymal disease Acute gout attack within 2 week study entry History drug abuse last 2 year , include narcotic , cocaine , alcohol ( great 21 drinks/week ) Arm circumference great 52 cm , precludes measurement 'thigh ' BP cuff History reaction allopurinol chlorthalidone Pregnant planning become pregnant study , breastfeed History noncompliance , unable comply study requirement , currently participate another study Not fast prior obtain screen laboratory data . If participant clearly fast , exclude individual casual blood glucose level great equal 200 mg/dL . In event fasting blood sugar exceed 126 mg/dL , reconfirm blood glucose measurement obtain subsequent day , per American Diabetes Association criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>